NRIX Nurix Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NRIX

Price (delayed)

$23.38

Market cap

$2.43B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.46

Enterprise value

$2.42B

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 24

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer ...

Highlights
NRIX's quick ratio is down by 8% year-on-year but it is up by 4.9% since the previous quarter
The net income has dropped by 65% year-on-year and by 16% since the previous quarter
The revenue has plunged by 58% YoY and by 49% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nurixtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of NRIX

NRIX stock price

How has the Nurix Therapeutics stock price performed over time
Intraday
-1.52%
1 week
1.12%
1 month
21.14%
1 year
102.78%
YTD
23.25%
QTD
-3.63%

Financial performance

How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$36.77M
Gross profit
$36.77M
Operating income
-$361.18M
Net income
-$341.35M
Gross margin
100%
Net margin
-928.4%
NRIX's net margin has dropped by 126% since the previous quarter
Nurix Therapeutics's operating margin has shrunk by 124% QoQ
The net income has dropped by 65% year-on-year and by 16% since the previous quarter
The revenue has plunged by 58% YoY and by 49% from the previous quarter

Price vs fundamentals

How does NRIX's price correlate with its fundamentals

Growth

What is Nurix Therapeutics's growth rate over time

Valuation

What is Nurix Therapeutics stock price valuation
P/E
N/A
P/B
6
P/S
70.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.71
NRIX's EPS is down by 33% year-on-year and by 9% since the previous quarter
The stock's price to book (P/B) is 131% more than its 5-year quarterly average of 2.6 and 94% more than its last 4 quarters average of 3.1
NRIX's equity is down by 16% since the previous quarter and by 10% year-on-year
The stock's price to sales (P/S) is 168% more than its last 4 quarters average of 26.4
The revenue has plunged by 58% YoY and by 49% from the previous quarter

Efficiency

How efficient is Nurix Therapeutics business performance
NRIX's return on sales has dropped by 126% since the previous quarter
The ROE has plunged by 68% YoY and by 19% from the previous quarter
NRIX's return on invested capital has dropped by 65% year-on-year and by 18% since the previous quarter
NRIX's return on assets has dropped by 65% year-on-year and by 18% since the previous quarter

Dividends

What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRIX.

Financial health

How did Nurix Therapeutics financials performed over time
The total assets has declined by 16% since the previous quarter and by 9% year-on-year
Nurix Therapeutics's total liabilities has decreased by 14% QoQ and by 8% YoY
NRIX's debt is 86% smaller than its equity
The debt to equity has increased by 17% since the previous quarter and by 17% year-on-year
NRIX's equity is down by 16% since the previous quarter and by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.